- Home
- INAB
INAB
IN8bio Inc.
as 12-23-2024 10:40am EST
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 24.0M | IPO Year: | 2021 |
| Target Price: | $7.75 | AVG Volume (30 days): | 750.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $1.93 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest IN8bio Inc. News
INAB Breaking Stock News: Dive into INAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
GlobeNewswire
21 days ago
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
GlobeNewswire
a month ago
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
Zacks Small Cap Research
a month ago
INAB: Upcoming Presentations at SNO & ASH
GlobeNewswire
a month ago
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
a month ago
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
GlobeNewswire
2 months ago
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
Zacks Small Cap Research
3 months ago
INAB: Restructuring Narrows Focus to AML
Compare INAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INAB IN8bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.